Please assess the completion status of the following clinical trial:

Trial Title: Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Criteria for Inclusion:~1. ≥ 18 year old males or females~2. Documented measurable or evaluable solid tumor malignancy that is relapsed, refractory, locally advanced, or metastatic~3. Patients entered to MTD Cohort B must have:~   * Histologically or cytologically confirmed NSCLC~  * No prior therapy with erlotinib, gefitinib, or any other EGFR-kinase inhibitor~  * Previously documented exon 19 deletion and/or exon 21 L858R mutations~  * Measurable disease according to RECIST~4. Disease that is currently refractory to, or not amenable to, standard therapy~5. Disease that is currently not amenable to surgical intervention, due to either medical contraindications or nonresectability of the tumor~6. Karnofsky performance status ≥ 70%, life expectancy ≥ 3 months~7. No childbearing potential or use of effective contraception by all fertile male and female patients, during the study and for 3 months after the last dose of study drug~8. Ability to give written informed consent~Criteria for Exclusion:~1. Pregnant or lactating women~2. Primary CNS malignancies; active CNS metastases~3. Hematologic malignancies (includes: leukemia, any form; lymphoma; and multiple myeloma)~4. Active second malignancy or history of another malignancy within 2 years with the exception of:~   * Treated, non-melanoma skin cancers~  * Treated CIS of the breast or cervix~  * Controlled, superficial bladder carcinoma~  * T1a or b prostate carcinoma involving \< 5% of resected tissue and PSA within normal limits (WNL)~5. Any of the following hematologic abnormalities:~   * Hemoglobin ≤ 9.0 g/dL~  * ANC \< 1,500 per mm3~  * Platelet count \< 100,000 per mm3~6. Any of the following serum chemistry abnormalities:~   * Total bilirubin \> 1.5 × the ULN~  * AST or ALT ≥ 3 × the ULN (≥ 5 × if due to hepatic involvement by tumor)~  * Serum albumin \< 2.5 g/dL~  * Creatinine ≥ 1.5 × ULN (or calculated CLCR \< 50 mL/min/1.73 m2)~7. Significant cardiovascular disease, including:~   * CHF requiring therapy~  * Ventricular arrhythmia requiring therapy~  * Any conduction disturbance (including patients with QTc interval prolongation \> 0.47 sec, history of a severe arrhythmia, or history of a familial arrhythmia \[eg, WPW\])~  * Angina pectoris requiring therapy~  * LVEF \< 50% by MUGA or Echocardiogram~  * Uncontrolled HTN~  * MI within 6 months of study entry~  * NYHA \> Class I~8. Significant gastrointestinal abnormalities, including:~   * Requirement for IV alimentation~  * Prior surgical procedures affecting absorption~  * Active peptic ulcer disease~  * ≥Grade 2 diarrhea due to any etiology~9. Known history of significant ophthalmologic abnormalities, including:~   * Severe dry-eye syndrome~  * Keratoconjunctivitis sicca~  * Sjogren's syndrome~  * Severe exposure keratopathy~  * Disorders increasing risk for epithelium-related complications~10. Serious/active infection; infection requiring parenteral antibiotics~11. Inadequate recovery from prior antineoplastic therapy~12. Inadequate recovery from any prior surgical procedure; major surgical procedure within 2 weeks~13. Life-threatening illness or organ system dysfunction compromising safety evaluation~14. Psychiatric disorder, altered mental status precluding informed consent or necessary testing~15. Inability to comply with protocol requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Daily oral administration of AV-412

Based on this trial design, predict the completion outcome and termination type (if applicable).